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outcome of the HTA recorded and the impact of the biomarker test on the submission 
outcome was graded as high, medium or low according to its inﬂ uence on the ﬁ nal 
decision. These ﬁ ndings were summarised, and 6 drugs were selected as case studies in 
order to identify key lessons relating to the risks, consequences, and ethical consider-
ations of Diagnostic/Treatment partnering. RESULTS: The review identiﬁ ed ﬁ ve bio-
markers in the ﬁ ve treatment areas of: HIV, Gastrointestinal stromal tumour (GIST), 
Non-small cell lung cancer (NSCLC), Colorectal cancer (CRC), and Breast cancer. 
Markers Her2 and K-RAS had a high impact in all included submissions, with 100% 
and 63% of these submissions resulting in a positive recommendation. In contrast, 
marker EGFR had a lower impact (not mentioned in 4 out of 10 submissions), with 
60% of these submissions being approved, and 40% rejected. The agencies most likely 
to reject a surrogate-outcome submission were PBAC (Australia) and SMC (Scotland) 
with rejection rates of 57% and 66% respectively, whereas CADTH accepted 100% of 
included submissions. CONCLUSIONS: Findings indicate ﬁ rstly that substantially dif-
ferent evidence requirements exist between HTA bodies in the markets considered (e.g. 
differing accuracy acceptability thresholds, prospective/retrospective analysis and the 
importance of cost-effectiveness), and secondly there are several ethical considerations 
to the selection or deselection of patients for treatment.
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HTAINSITE: A DATABASE OF NICE SUBMISSIONS AND DECISIONS
Howard S, Harper C, Poppe P
Abacus International, Bicester, Oxon, UK
OBJECTIVES: HTAinSite is an on-line, subscription-based database of all NICE 
Technology Appraisals (TAs). It includes information relating to submitted evidence, 
appraisal process and ﬁ nal decision and enables assessment of associated trends. 
METHODS: An academic steering group designed and agreed the data extraction 
protocol. a team of reviewers conducted the initial data extraction, which was vali-
dated by a second reviewer. Historical extraction is complete, with on-going TAs 
extracted on a monthly basis. RESULTS: A total of 181 TAs have been extracted to 
date, 5 of which were terminated, resulting in 176 complete TAs relating to 326 tech-
nologies. Of these, 53% were awarded a restricted decision, 32% were fully recom-
mended and 16% rejected. Of the three most commonly appraised disease areas (cancer, 
cardiovascular (CVS), central nervous system (CNS); CVS technologies were least com-
monly rejected by NICE (3% vs. 21% for cancer and 17% for CNS). Of the four most 
commonly used assessment groups (Shefﬁ eld, York, Southampton and Birmingham); 
technologies assessed by Shefﬁ eld were most commonly rejected (28%) and those by 
York were least commonly rejected (4%). Technologies supported by a patient submis-
sion were less commonly rejected than those without (15% vs. 29%). a total of 35 TAs 
(20%) resulted in an appeal, no appeals were upheld entirely, all appeals were upheld 
partially. HTAinSite also allows detailed analysis of individual TAs and cross-compar-
ison between TAs as well as identifying trends between submitted evidence (acquisition 
costs, budget impact, cost-effectiveness and clinical effectiveness) and ﬁ nal outcome. 
These additional analyses will be further explored in the poster and preliminary results 
will also be updated. CONCLUSIONS: HTAinSite is a useful tool for anyone interested 
in understanding the relationship between submitted evidence and ultimate NICE 
decision. The HTAinSite format may be useful for other HTA bodies, depending on 
the public availability of relevant information.
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ECONOMIC EVIDENCE REQUIREMENTS: COMPARISON BETWEEN HTA 
AGENCIES AND IMPLICATIONS FOR MANUFACTURERS
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OBJECTIVES: Mathematical models are required by decision makers to provide 
insight into pharmcoeconomic beneﬁ ts associated with a product. It is therefore 
essential that manufacturers understand economic evidence requirements when sub-
mitting an application to a Health Technology Assessment (HTA) agency. METHODS: 
A literature search of economic recommendations from the following HTA agencies 
was conducted: CADTH (Canada), HAS (France), IQWiG (Germany), NICE 
(England), PBAC (Australia), PHARMAC (New Zealand) and SMC (Scotland). 
RESULTS: Cost-effectiveness analysis is considered the most relevant analytical tech-
nique across the English-speaking agencies with a preference for QALY-based analysis, 
in contrast to IQWiG which does not consider QALYs and utilities as central to their 
methods. Unlike other HTA agencies assessed, the French agency HAS does not cur-
rently require cost-effectiveness modelling in its decision-making process. EQ-5D is 
the most commonly used utility instrument, NICE being the most prescriptive agency 
in this regard. However, utilities mapped from disease-speciﬁ c quality of life measures 
may be accepted and agencies such as PBAC and IQWiG express no formal preference 
between instruments. The third-party payer is the most commonly required perspective 
adopted across the English-speaking agencies while IQWiG and PBAC recommend a 
societal perspective in addition to the payer’s perspective. This trend towards a 
broader, societal perspective may, however, be limited by uncertainties around mea-
surement of wider costs. Sensitivity analyses are required by all agencies to explore 
uncertainty in the model. NICE and CADTH both favor a probabilistic approach 
while PBAC prefers univariate and multivariate analyses. Other agencies expect the 
manufacturer to justify their approach and choice. CONCLUSIONS: The recommen-
dations of IQWiG and PBAC differ from the other selected agencies. Uniquely, in 
France the pharmaeconomic case is considered separately from the HTA process by 
the French Health Economists Association. These differences between agencies should 
be considered when planning evidence generation activities to support economic model 
development.
PHP108
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OBJECTIVES: Health Technology Assessment (HTA) agencies require various types 
and qualities of evidence for clinical effectiveness evaluations due to differences in 
health care systems and policies. It is essential for manufacturers to understand these 
requirements when submitting an application to each individual HTA agency. 
METHODS: A literature search of clinical recommendations from the following HTA 
agencies was conducted for comparison: CADTH (Canada), HAS (France), IQWiG 
(Germany), NICE (England), PBAC (Australia), PHARMAC (New Zealand) and SMC 
(Scotland). RESULTS: The choice of the optimal comparator is crucial to the outcome 
of the HTA. Almost all agencies prefer comparison versus the most frequently used 
interventions except for PBAC which requires comparison to the interventions most 
likely to be displaced. All HTA agencies are cautious in their interpretation of sur-
rogate outcomes (SO) and require manufacturers to provide evidence linking the SO 
to ﬁ nal patient-relevant outcomes. PBAC has notably developed a framework for 
assessing SOs and the impact of these on uncertainty in HTA submissions. Most 
agencies except for NICE clearly state their position on the deﬁ nition and the use of 
SOs. All agencies recognize the value of observational studies in reﬂ ecting real-world 
situations and providing long-term data although RCTs provide the key evidence on 
comparative effectiveness. Systematic reviews (SR) of clinical evidence are essential to 
present comparative effectiveness relative to all comparators. Contrary to most agen-
cies, HAS prefers SRs but does not require them and bases its assessments mainly on 
pivotal clinical trials provided by the manufacturer. NICE and IQWiG also differ from 
the other agencies as they perform in-house SR in addition to the manufacturer’s. 
CONCLUSIONS: The differences between agency requirements are subtle and mean 
that manufacturers need to put together a solid clinical evidence package needing very 
little adaptation to meet the seven country requirements.
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OBJECTIVES: The EUnetHTA Joint Action (2010–2012) is a joint initiative by EU 
Member States and the European Commission to advance European collaboration on 
health technology assessment (HTA). Part of the EUnetHTA Joint Action aims at 
reviewing methods used for the relative effectiveness assessment (REA) of pharmaceu-
ticals and to develop, apply and ﬁ eld-test tools and methods. As a ﬁ rst step towards 
this goal, objectives, processes and methodologies used for REA by HTA organizations 
across Europe and other countries are summarised. This overview is crucial for the 
development of shared or common methodologies to be used in future REA across 
Europe. METHODS: Data were captured with a standardised data abstraction form. 
Data were initially abstracted from different types of literature (peer reviewed, grey 
literature, EU and national reports etc.). Where there were gaps in the data, telephone 
interviews were arranged with a relevant person at the respective HTA or reimburse-
ment agency. RESULTS: Most European countries carry out some form of REA, 
however the deﬁ nitions of the assessments in general are not consistent with the deﬁ ni-
tion by the Pharmaceutical Forum. In addition the scope (inclusions of beneﬁ t-risk 
analysis and/or a cost-effectiveness analysis), the process (timing, involvement of 
stakeholders and separation of assessment and appraisal phase) and the purpose 
(inform clinical decision-making, reimbursement and/or for pricing decision-making) 
of the assessments vary as well as the methods (such as inclusion of surrogate end-
points, composite endpoints and quality of life data and extrapolation of efﬁ cacy 
data). Most agencies publish a guideline for the methodology used for REA however 
few publish them in English. CONCLUSIONS: A considerable number of European 
countries carry out REAs. However, the purpose and the methodology used vary 
across Europe. The reasons behind these differences need to be considered in the 
development of a common European methodology for REA. 
HEALTH CARE USE & POLICY STUDIES – Population Health
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PHYSICIANS’ VIEWS OF THE RELATIVE IMPORTANCE OF SELECTED 
MEDICAL INNOVATIONS ON THE GREEK POPULATION HEALTH 
STATUS
Athanasakis K, Karampli E, Kyriopoulos J
National School of Public Health, Athens, Greece
OBJECTIVES: To identify the pharmaceutical and medical innovations that contributed 
mostly to the improvement of Greek population health status during the last three 
decades, according to physicians’ views. METHODS: Building on the methodology by 
Fuchs and Sox, a questionnaire based survey was conducted on a representative sample 
of 500 Greek internists and general practitioners aged ≥50 years old. The study question-
naire was formulated by a panel of experts, with the use of the Delphi method and 
included one list of 22 pharmaceutical and a second list of 20 medical innovations. 
Physicians were asked to identify the seven more important and seven least important 
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innovations, with regard to their impact on patients’ health status. RESULTS: Response 
rate was 78%. The seven most important pharmaceutical innovations reported were 
Angiotensin Converting Enzyme (ACE) inhibitors and angiotensin II antagonists, inhaled 
steroids and β2-agonists, statins, proton pump inhibitors and H2-antagonists, novel 
antibiotics, antiviral drugs for hepatitis  and C and calcium channel blockers. The seven 
most important technological innovations were: magnetic resonance imaging (MRI) and 
computed tomography scanning (CT), balloon angioplasty with stents, Coronary Artery 
Bypass Graft (CABG), gastrointestinal endoscopy, Human Immunodeﬁ ciency Virus 
testing, mammography and Prostate-Speciﬁ c Antigen (PSA) testing. In both cases, inno-
vations that ranked higher were used to treat high-prevalence diseases with a signiﬁ cant 
contribution on the burden of disease for the Greek population. In addition, innovations 
that contributed to improvements in disease diagnoses and management were also 
ranked higher. CONCLUSIONS: the epidemiological proﬁ le of the population, the 
effectiveness of each innovation in terms of clinical effectiveness as well as health-related 
quality of life, and the utility of the innovation in everyday clinical practice constitute 
important determinants of the physicians’ opinions regarding the relative importance of 
medical innovations on the health status of the Greek population.
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OBJECTIVES: To analyze and predict trends in utilization of preventive care services 
in a United States population using a national database. Several national reports and 
evidence in literature indicate disparities in the utilization of preventive care services 
but only few have predicted utilization patterns of preventive care services. METHODS: 
The 2007 Medical Expenditure Panel Survey (MEPS), a national probability sample 
survey of the ambulatory civilian US population, was analyzed to determine demo-
graphic patterns of utilization. Utilization of blood pressure screening, cancer screen-
ing (mammography, colonoscopy/sigmoidoscopy, pap smear and breast), cholesterol 
and dental checkup and ﬂ u vaccination were used as the dependent variables while 
age, gender, race/ ethnicity, annual income insurance status and perceived health status 
were used as independent variables. Descriptive statistics were used to describe the 
population; univariate chi-squared analysis was used to determine group differences 
for the categorical variables. Multivariate logistic regression model was built to predict 
odds of utilization of services. All analyses were carried out using SAS v9.1. RESULTS: 
Utilization of preventive care services was found to be high for blood pressure (n = 
17,959, 89.0%) and cholesterol (n = 14,956, 94.7%) checkup and low for ﬂ u vaccina-
tion (n = 30,964, 21.2%). Signiﬁ cant chi square differences in utilization of preventive 
care services were found for most of the dependent variables (P < 0.001), save for 
colonoscopy/sigmoidoscopy screening. Regression model showed that young women 
(20–30 years) with higher income were more likely to obtain breast exams (OR = 
10.584; CI = 4.312–25.980) compared with young women earning lower income 
(<$20,000). Odds of utilization were nearly similar for all races. However, Hispanics 
were more likely to obtain a colonoscopy/sigmoidoscopy (OR = 3.069; CI = 2.216–
4.250) compared with non-Hispanics. The uninsured generally had lower odds of 
utilization across almost all preventive care services. CONCLUSIONS: This study was 
successful in identifying age, race, income and insurance status-related disparities and 
in predicting preventive care service utilization in a US population. 
HEALTH CARE USE & POLICY STUDIES – Prescribing Behavior & 
Treatment Guidelines
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ANALYSIS OF PHARMACISTS’ INTERVENTIONS OF ELECTRONIC 
PRESCRIPTIONS AT SULTAN QABOOS UNIVERSITY HOSPITAL IN 
OMAN
Al-Rashdi IS, Victoria M, Susan S, Al-Zakwani IS
Sultan Qaboos University, Al-Khoudh, Oman
OBJECTIVES: To evaluate the number and types of pharmacists’ interventions of 
electronic prescriptions at Sultan Qaboos University (SQU) hospital in Oman. 
METHODS: This was a prospective study where interventions on electronic prescrip-
tions over one-year (2009) at SQU hospital were evaluated. a standard data collection 
form was used to capture the data related to drug choice and drug regimen. Clinical 
relevance was deﬁ ned as to whether efﬁ cacy or toxicity was either improved or 
reduced. Clinical relevance was based on the judgments of at least two pharmacists. 
Analyses were performed using descriptive statistics. RESULTS: A total of 1,123 
interventions were recorded out of 186,353 prescriptions (intervention rate/prescrip-
tion = 0.6%) and 454,654 items (intervention rate/item = 0.25%) dispensed. During 
the year, only 3% of the interventions were administrative (absence of doctor’s sig-
nature/wrong patient’s card) while 97% were clinical. The clinical interventions were 
categorized into drug regimen (n = 886; 74%) and drug choice (n = 313; 26%). Almost 
62% (n = 547) of the problems associated with drug regimen were related to wrong 
doses. The three most common drug choice issues included wrong formulations (n = 
107; 34%), wrong drug (n = 62; 20%) and deletion (n = 62; 20%). Efﬁ cacy improved 
in 52% (n = 588) of the cases, avoided toxicity in 29% (n = 324) and avoided unneces-
sary exposure in 19% (n = 211). Interventions prevented organ damage in 1.7% (n = 
20) of the cases, major in 17% (n = 188), moderate in 49% (n = 550) and minor in 
32% (n = 364). The mean time (±SD) spent per prescription was 11 ± 9 minutes. 
CONCLUSIONS: The data show that out-patient pharmacists play an important role 
in drug safety and optimization of pharmaceutical care.
PHP113
LEVELS OF MEDICATION USE AMONG GERIATRIC PATIENTS IN 
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OBJECTIVES: Adequate levels of medication are critical among elderly patients given 
the existence of co-morbidities and impaired levels of functioning. Using patient data 
collected via a web-based information system, we investigated the average number of 
items prescribed to geriatric patients treated in Acute Geriatric and Remobilisation 
Units (AG/R) in Austria between January 2008 and December 2009. We investigated 
the association of age with medication levels and assessed whether treatment in an 
AG/R led to changes in levels of medication. METHODS: The standardised data set 
developed by QiGG was made available by AG/Rs using the geriatric module of the 
online information system “Healthgate BARS”. We assessed patients’ medication data 
including number of prescribed items at admission and discharge. Baseline character-
istics (including age) were assessed. Additionally, changes in medication prescriptions 
during the stay were documented. RESULTS: Data from 14,923 stays were analyzed. 
Patients were prescribed a mean of 8.4 agents (±3.6) at admission which was signiﬁ -
cantly reduced to a mean of 8.0 (±3.35) at discharge after a mean length of stay of 
18.9 (±14.1) days. a reduction in levels of medication was observed among all age 
groups (young-old: −74, middle-old: 75–84, oldest-old: 85+).The oldest old had the 
lowest mean number of prescriptions at both admission (8.1 ± 3.4) and discharge (7.6 
± 3.1). There was an overall increase in documented changes to prescriptions (either 
in number or type of medications) during this period from 61.1% to 80.1%. CON-
CLUSIONS: The observed reductions in levels of medication across all analyzed 
groups during (in-patient) stays in AG/Rs, as well as the documented changes in 
prescriptions, may suggest increased awareness both of over-prescription and the 
necessity of adequate medication levels in special geriatric care.
PHP114
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OBJECTIVES: Both observed and unobserved bias in observational claims data are 
controlled with instrumental variable approach. However, it is difﬁ cult to ﬁ nd a valid 
instrument that is strongly correlated with treatment choice but not directly correlated 
with outcomes. In this paper, we derived doctors’ prescribing patterns from the claims 
data and examined their validity. METHODS: Based on U.S. claims data, we assigned 
patients a unique doctor based on the greatest number of ofﬁ ce visits during the 6 
months pre-index period. For each physician, and for each 6-month calendar block 
of time, we estimated the physician preference as the time-varying proportion of 
patients treated with selective serotonin reuptake inhibitors (SSRIs) and serotonin–
norepinephrine reuptake inhibitors (SNRIs) during that interval. We applied Shea’s 
partial R-square method, the Anderson canonical correlation, and Cragg-Donald tests 
to check if doctors’ prescribing patterns were weak instruments. RESULTS: Tests 
showed that doctors’ prescribing patterns are a valid and strong instrument for out-
comes research studies. We showed that patients were more likely to be prescribed 
generic SSRIs relative to non-generic SSRIs if doctors’ prescribing patterns favored 
generic prescription (p = 0.000). Similarly, patients were less likely to be in the SSRIs 
group if doctors’ prescribing patterns favored SNRI prescriptions (p = 0.000). We 
showed that the treatment coefﬁ cient on the adherence model that does not control 
for the unobserved bias was 10% lower than the one that uses the instrumental vari-
able method. CONCLUSIONS: Doctors’ prescribing patterns are important factors 
for prescription decisions. Any outcomes research models such as compliance, adher-
ence or treatment effect studies should incorporate these patterns. Models that fail to 
control for these variables might contain omitted variable bias.
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THE INCORPORATION OF ECONOMIC EVIDENCE IN THE DUTCH 
CLINICAL PRACTICE GUIDELINES
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OBJECTIVES: Because economic evaluations aim to decrease practice variations and 
advocate (cost)-effective interventions, their use in the formulation of practice 
